| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1556-0864(15)30414-7 |
| P698 | PubMed publication ID | 17409968 |
| P2093 | author name string | Frances A Shepherd | |
| Lesley Seymour | |||
| Marlo Whitehead | |||
| Gary M Clark | |||
| Michelle Savoie | |||
| Denni M Zborowski | |||
| Jennifer L Culbertson | |||
| P2860 | cites work | The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis | Q34986549 |
| The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival | Q35976186 | ||
| Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? | Q36140967 | ||
| Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival | Q36467797 | ||
| Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer | Q36695371 | ||
| Extensive experience of disease control with gefitinib and the role of prognostic markers | Q37360495 | ||
| Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer | Q40489484 | ||
| Dangers of using "optimal" cutpoints in the evaluation of prognostic factors | Q40752297 | ||
| Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer | Q42465729 | ||
| Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer | Q45073535 | ||
| Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer | Q45246415 | ||
| Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections | Q47316045 | ||
| Co-expression of epidermal growth factor receptor and transforming growth factor-α is independent of ras mutations in lung adenocarcinoma | Q57272677 | ||
| Why do so many prognostic factors fail to pan out? | Q67550894 | ||
| Do we really need prognostic factors for breast cancer? | Q72776924 | ||
| Immunocytochemical markers in stage I lung cancer: relevance to prognosis | Q73585186 | ||
| Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC? | Q81405939 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? | Q33538461 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. | Q34436986 | ||
| Interpreting and integrating risk factors for patients with primary breast cancer | Q34482412 | ||
| Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. | Q34535487 | ||
| Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. | Q34536780 | ||
| Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. | Q34554584 | ||
| Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer | Q34557318 | ||
| Erlotinib in lung cancer - molecular and clinical predictors of outcome | Q34559274 | ||
| P433 | issue | 8 | |
| P921 | main subject | erlotinib | Q418369 |
| non-small-cell lung carcinoma | Q3658562 | ||
| P304 | page(s) | 837-846 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Journal of Thoracic Oncology | Q2448056 |
| P1476 | title | Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib | |
| P478 | volume | 1 |
| Q35229741 | A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer |
| Q89591831 | An overview of precision oncology basket and umbrella trials for clinicians |
| Q37479225 | Analytic variability in immunohistochemistry biomarker studies. |
| Q37133974 | Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies. |
| Q37539427 | Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. |
| Q33525226 | Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients |
| Q37799927 | Do we have markers to select patients for adjuvant therapies of non-small-cell lung cancer? |
| Q35699888 | EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology |
| Q33870594 | Effective incorporation of biomarkers into phase II trials |
| Q36040002 | Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis |
| Q35971552 | Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. |
| Q88105993 | Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis |
| Q36942514 | Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland |
| Q33561588 | Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme |
| Q90331241 | MUC4 isoforms expression profiling and prognosis value in Chinese melanoma patients |
| Q41997163 | Orbital metastases as the first manifestation of lung adenocarcinoma. |
| Q37155636 | Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers |
| Q36310182 | Personalized medicine in breast cancer: a systematic review |
| Q101403266 | Prognostic and predictive parameters in breast pathology: a pathologist's primer |
| Q41251482 | Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib |
| Q30514241 | Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration |
| Q59822429 | Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration |
| Q33598706 | Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemia |
| Q34030379 | Targeted Therapies in Lung Cancer |
| Q37102068 | The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement |
| Q53826389 | Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer. |
Search more.